GS
PTLA

GAM Systematic’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

GAM Systematic’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-568
Closed -$29K – 711
2015
Q4 		$29K Buy
+568
New +$27.5K 0.01% 602

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

GAM Systematic's PTLA Position: Q1 2016 in Review

GAM Systematic sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2016, closing a stake of 568 shares — an estimated $29K sold.

GAM Systematic first reported a position in PTLA in Q4 2015 and held it in 1 quarter. The position peaked at $29K in Q4 2015. 167 funds tracked by Wall St. Rank hold PTLA as of Q1 2016.

  • GAM Systematic reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
  • GAM Systematic sold 568 Portola Pharmaceuticals, Inc. shares in Q1 2016, an estimated $29K.
  • GAM Systematic first reported a position in Portola Pharmaceuticals, Inc. in Q4 2015 and held it in 1 quarter.
  • GAM Systematic's Portola Pharmaceuticals, Inc. position peaked at $29K in Q4 2015.
  • 167 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2016.

Based on GAM Systematic's 13F filing for Q1 2016, filed 13 May 2016.